Solid Biosciences Inc.
About Solid Biosciences Inc.
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2022
- $8.1M
- Net income
- -$117.2M
- Total assets
- $232.5M
- Market cap
- $659.6M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $179.2M
- Operating income
- -$179.2M
- Income tax
- $0
- Net income
- -$174.3M
- EPS (basic)
- $-1.99
- EPS (diluted)
- $-1.99
Balance sheet
- Total assets
- $232.5M
- Current assets
- $205.5M
- Total liabilities
- $52.5M
- Current liabilities
- $33.5M
- Shareholders’ equity
- $180.0M
Cash flow
- Operating cash flow
- -$156.3M
- Investing cash flow
- -$58.5M
- Financing cash flow
- $194.4M
- Net cash flow
- -$20.3M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $659.6M
- EPS (diluted)
- $-1.99
- Shares outstanding
- 102.9M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jan 25, 2018
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $117.2M in FY2022.
- Trading 26% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Solid Biosciences Inc..
Write a review
News about Solid Biosciences Inc.
News & sentiment via Polygon.io
